{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+oral+form&page=2",
    "query": {
      "intervention": "Placebo - oral form",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+oral+form&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T16:25:09.203Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06136195",
      "title": "Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alcohol Consumption",
        "Heavy Drinker",
        "Alcohol Use Disorder (AUD)"
      ],
      "interventions": [
        {
          "name": "Mavoglurant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 63,
      "start_date": "2024-07-01",
      "completion_date": "2028-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-09-26T16:25:09.203Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06136195"
    },
    {
      "nct_id": "NCT01801917",
      "title": "Efficacy and Tolerability of BAF312 in Patients With Polymyositis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Polymyositis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "BAF312",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 14,
      "start_date": "2013-04-24",
      "completion_date": "2016-08-05",
      "has_results": true,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-09-26T16:25:09.203Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01801917"
    },
    {
      "nct_id": "NCT06637631",
      "title": "A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "SAR441566",
          "type": "DRUG"
        },
        {
          "name": "SAR441566 matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 260,
      "start_date": "2024-12-10",
      "completion_date": "2026-10-14",
      "has_results": false,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-09-26T16:25:09.203Z",
      "location_count": 19,
      "location_summary": "Sun City, Arizona • Bristol, Connecticut • Clermont, Florida + 16 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Bristol",
          "state": "Connecticut"
        },
        {
          "city": "Clermont",
          "state": "Florida"
        },
        {
          "city": "Homestead",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06637631"
    },
    {
      "nct_id": "NCT02926937",
      "title": "Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Sotagliflozin (SAR439954)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lexicon Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 399,
      "start_date": "2016-11-11",
      "completion_date": "2019-05-17",
      "has_results": true,
      "last_update_posted_date": "2021-06-21",
      "last_synced_at": "2026-09-26T16:25:09.203Z",
      "location_count": 56,
      "location_summary": "Tucson, Arizona • Anaheim, California • Canoga Park, California + 46 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02926937"
    },
    {
      "nct_id": "NCT07304024",
      "title": "A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Central Auditory Processing Disorder",
        "Hearing Impaired (Partially)",
        "Hearing",
        "Hearing Abnormality",
        "Hearing Disability",
        "Hearing Disorder",
        "Hearing Disorders",
        "Hearing Impairment, Sensorineural",
        "Hearing Handicap",
        "Hearing Impaired",
        "Hearing Impairment",
        "Hearing Loss",
        "Central Auditory Disease",
        "Noise Exposure",
        "Noise Induced Hearing Loss",
        "Noise-Induced Hearing Loss",
        "Sound Perception",
        "Myelin Degeneration",
        "Myelinopathy",
        "Myelin Integrity",
        "Remyelination",
        "Hidden Hearing Loss",
        "Cocktail Party Skill",
        "Cocktail Party Syndrome",
        "CAPD",
        "Age Problem"
      ],
      "interventions": [
        {
          "name": "Clemastine Fumarate Combined With Engineered Sound",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Clemastine Fumarate Combined With Pink Noise",
          "type": "DRUG"
        },
        {
          "name": "Placebo Drug With Engineered Sound",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo - Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "45 Years to 65 Years"
      },
      "enrollment_count": 344,
      "start_date": "2025-03-31",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-09-26T16:25:09.203Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07304024"
    },
    {
      "nct_id": "NCT00922636",
      "title": "A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "LY2216684",
          "type": "DRUG"
        },
        {
          "name": "Methylphenidate",
          "type": "DRUG"
        },
        {
          "name": "Placebo (tablet)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (capsule)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 340,
      "start_date": "2009-06",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2014-08-18",
      "last_synced_at": "2026-09-26T16:25:09.203Z",
      "location_count": 17,
      "location_summary": "Spring Valley, California • Bradenton, Florida • Gainesville, Florida + 14 more",
      "locations": [
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00922636"
    },
    {
      "nct_id": "NCT01731171",
      "title": "Probiotics to Prevent Relapse After Hospitalization for Mania",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bipolar Disorder",
        "Schizoaffective Disorder"
      ],
      "interventions": [
        {
          "name": "Probiotic Supplement",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Inert Compound",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Sheppard Pratt Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 66,
      "start_date": "2012-11",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2019-01-07",
      "last_synced_at": "2026-09-26T16:25:09.203Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01731171"
    },
    {
      "nct_id": "NCT05405244",
      "title": "Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overweight and Obesity",
        "Eating Behavior"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Bromocriptine-QR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 55,
      "start_date": "2017-09-19",
      "completion_date": "2019-09-19",
      "has_results": true,
      "last_update_posted_date": "2022-09-07",
      "last_synced_at": "2026-09-26T16:25:09.203Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05405244"
    },
    {
      "nct_id": "NCT04625101",
      "title": "Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epileptic Encephalopathy",
        "Continuous Spike and Wave During Sleep"
      ],
      "interventions": [
        {
          "name": "NBI-827104",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "4 Years to 12 Years"
      },
      "enrollment_count": 24,
      "start_date": "2021-04-26",
      "completion_date": "2022-10-11",
      "has_results": true,
      "last_update_posted_date": "2025-09-05",
      "last_synced_at": "2026-09-26T16:25:09.203Z",
      "location_count": 8,
      "location_summary": "Orange, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04625101"
    },
    {
      "nct_id": "NCT02244619",
      "title": "PO vs. IV Acetaminophen Given Perioperatively for 24 hr Post-op Pain Control Following Total Hip or Knee Replacement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Post-op Pain"
      ],
      "interventions": [
        {
          "name": "Oral acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "IV acetaminophen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kettering Health Network",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 515,
      "start_date": "2014-09",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2017-07-24",
      "last_synced_at": "2026-09-26T16:25:09.203Z",
      "location_count": 1,
      "location_summary": "Kettering, Ohio",
      "locations": [
        {
          "city": "Kettering",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02244619"
    }
  ]
}